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Kathryn B. Garber1,*Let’s Hear It for Genetic Counselors
Much of what we know about the use of genetic testing
for inherited susceptibility to breast and ovarian cancer
comes from research studies performed at academic
medical centers. To get a broader look at the experience
of women who seek this testing, the ABOUT (American
BRCA Outcomes and Utilization of Testing) study re-
cruited women via requests for insurance coverage for
BRCA testing, thereby ensuring that tests ordered by a
variety of healthcare professionals in different settings
were represented in the sample. A recent paper from
the study highlights the value of genetic counseling
prior to testing for inherited cancer. Of the more than
3,000 women for whom testing was ordered, fewer
than 40% had received genetic counseling from a ge-
netics professional prior to the test request. Those
women who had received genetic counseling were
more knowledgeable about the test and expressed greater
satisfaction with the testing than those who did not
receive this counseling. Genetic counseling also aided
selection of the most appropriate candidates for this
type of test; women who received genetic counseling
were more than twice as likely to meet standard testing
guidelines than were the women who didn’t receive
counseling, and this translated into the fraction of
women who received insurance coverage for the test.
Although MDs of all stripes can order genetic testing,
this work emphasizes the value of the genetic counselor
for patients as they seek predictive testing for breast
cancer.
Armstrong et al. (2015). JAMA Oncol. Published online
October 1, 2015. http://dx.doi.org/10.1001/jamaoncol.2015.
3048.Gene-Expression Assay Guides Treatment of
Breast Cancer
Treatment guidelines recommend adjuvant chemo-
therapy for many women with localized breast cancer.
Even without chemotherapy, many of these women
would not go on to develop a recurrence, suggesting
that some of them are over-treated. The question has
been, how should these low-risk women be identified?
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The Americana gene-expression assay are available to guide these treat-
ment decisions for breast cancer. This TAILORx (Trial
Assigning Individualized Options for Treatment) study
assessed the use of the Oncotype DX 21-gene assay to
identify women who are at low risk of cancer recurrence
and who could avoid adjuvant chemotherapy. Nearly
16% of women enrolled in the study had a low-risk
expression profile and received endocrine therapy
without chemotherapy. After 5 years, the rate of freedom
from recurrence was 98.7%, indicating that it was safe to
avoid chemotherapy in these women, at least in the short
term. We will have to wait to hear the results from the
trial’s second installment, in which women with a mod-
erate risk score were randomly assigned to receive chemo-
therapy plus endocrine therapy or endocrine therapy
alone.
Sparano et al. (2015). N. Engl. J. Med. Published
online September 27, 2015. http://dx.doi.org/10.1056/
NEJMoa1510764.Enzyme-Replacement Therapy for Lysosomal Acid
Lipase Deficiency
Lysosomal acid lipase deficiency is an under-recognized
disorder associated with dyslipidemia and ultimately
results in liver damage. On the severe end of the
spectrum is the infantile-onset Wolman syndrome, which
is a fatal condition, but there are also later-onset forms
of the disease. Deficiency of this enzyme leads to
lysosomal accumulation of cholesteryl esters and triglyc-
erides and reduced production of free cholesterol.
Although they are still prescribed, typical lipid-lowering
agents, such as statins, have little effect in these patients.
A recent phase-three double-blind clinical trial of an
enzyme-replacement therapy for lysosomal acid lipase
deficiency in adults and children is quite promising.
The trial demonstrated that this drug—sebelipase alfa—
normalized levels of alanine amino transferase, a marker
of liver damage, in nearly one-third of patients treated
for 20 weeks. At the same time, levels of low-density lipo-
protein cholesterol and triglycerides decreased, and levels
of high-density lipoprotein cholesterol increased. Addi-
tional improvements in these measures occurred during
an open-label extension trial. This work makes it more
critical to identify individuals with lysosomal acid lipaseta, GA 30322, USA
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deficiency because targeted treatment appears to be
effective.
Burton et al. (2015). N. Engl. J. Med. 373, 1010–1020.Diet-Based Natural Selection
Massive genome-wide association studies (GWASs) have
had splashy success in identifying genetic variation that
contributes to body morphology and many other traits
in general populations, but there is still a role for
smaller-scale approaches in uncovering contributory vari-
ation. One way to do this is to start with a population that
is at the extreme end of a trait. In essence, that is the
angle used by Fumagalli et al., who sought signatures of
positive selection in an Inuit population adapted to a
diet rich in omega-3 polyunsaturated fatty acids and a
cold climate. The genomic region with the strongest
signal of selection includes the genes encoding three
fatty-acid desaturases. Using about 4,000 individuals, the
authors were able to show that the alleles under selection
are associated with multiple metabolic and morphometric
phenotypes, particularly weight and height. The relevant
minor alleles are much more rare in Europeans and so
were missed by other GWASs, but with a combined sam-630 The American Journal of Human Genetics 97, 629–630, Novembple of more than 200,000 Europeans, the association
with height is confirmed.
Fumagalli et al. (2015). Science 349, 1343–1347.An Abundance of Sequence
How might one summarize data from two massive
sequencing projects in just a few sentences? I admit—it is
daunting. The pair of papers from the final phase of the
1000 Genomes Project present the spectrum of sequence
and structural variation in more than 2,000 individuals
from 26 populations and are complemented nicely by
the UK10K project, which reports sequence from a larger
number of samples but from a single population. Some
of the tidbits I found most interesting were that previously
cryptic structural variation in linkage disequilibrium with
single-nucleotide variants might explain previous disease
associations and that the authors compare results from as-
sociation studies by using common and rare variants for a
variety of traits.
1000 Genomes Project Consortium. (2015). Nature 526,
68–74.
Sudmant et al. (2015). Nature 526, 75–81.
UK10K Consortium. (2015). Nature 526, 82–90.This Month in Our Sister JournalsYeast-Based Platform for Assessing Human
Variation
The deluge of sequence variation discovered through large-
scale sequencing leads to a bottleneck at the level of
functional assessment. To facilitate screening of genetic
variation, Hamza et al. assessed human-yeast cross-species
complementation to identify human cDNAs that could
rescue lethality caused by null mutations in yeast. This
sets up a system by which sequence variation within
the complementing human gene can be assessed for
function in the yeast. Overall, the researchers found 65human cDNAs that complemented the null allele of 58
essential yeast genes. To test their system, they focused
on yeast chromosome-instability mutants in order to
assess sequence variants found in the complementing hu-
man genes in tumors. In general, they found that some
variants complemented the null allele and others did not
and that computational predictions did not always antici-
pate to which category a variant would belong. The vari-
ants that failed to complement can be prioritized for
further characterization of their role in tumorigenesis.
Hamza et al. (2015). Genetics. Published online September 9,
2015. http://dx.doi.org/10.1534/genetics.115.181099.er 5, 2015
